United States of America
Status: affected by circulating vaccine-derived poliovirus type 2 (cVDPV2)
Following the isolation of vaccine-derived poliovirus type 2 (VDPV2) in New York in July 2022, further virological and epidemiological analysis confirms circulation of this strain.
New York and US public health authorities continue to implement a timely and appropriate response to this circulating VDPV2 (cVDPV2), in order to rapidly interrupt its circulation, including by: continuing to intensify surveillance efforts (including for potential cases of paralysis), identifying population sub-groups/areas with potential immunity gaps, and proactively reaching out to communities with known immunity gaps to strengthen vaccination coverage.
Polio this week in United States of America
- No case of circulating vaccine-derived poliovirus type 2 (cVDPV2) was reported this week. One cVDPV2 case was reported in New York in 2022.
- No circulating vaccine-derived poliovirus type 2 (cVDPV2) positive environmental sample was reported this week. There were 12 positive samples reported in 2022.
International Health Regulations
United States of America are classified by the International Health Regulations (IHR) as a state infected with cVDPV2, with or without evidence of local transmission. It is therefore subject to Temporary Recommendations issued by the International Health Regulations Emergency Committee on Polio Eradication (issued as of January 2023).
WHO’s International Travel and Health recommends that all travellers to polio-affected areas be fully vaccinated against polio. Residents (and visitors for more than 4 weeks) from infected areas should receive an additional dose of OPV or inactivated polio vaccine (IPV) within 4 weeks to 12 months of travel.